Compass

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
星期四, 五月 9, 2024
MIBC, FDA, Cancer, Urology, Fast Track, Necrosis, SPA, Safety, General counsel, Research, Recurrence, Growth, Light, Bladder cancer, Immunogenic cell death, Incidence, Patient, Enrollment, Compass, Macrophage, NMIBC, Neoplasm, Annual general meeting, Damage-associated molecular pattern, ARVO, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024
    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
  • “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9 million.
  • General and administrative expenses include $1.4 million and $1.1 million of stock-based compensation for the three months ended March 31, 2024 and 2023, respectively.

CMP INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Compass Minerals International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
星期四, 五月 9, 2024
Compass, Compass Minerals, Complaint, Court, Person

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Compass Minerals International, Inc. (“Compass Minerals” or “the Company”) (NYSE: CMP) and certain of its officers.

Key Points: 
  • NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Compass Minerals International, Inc. (“Compass Minerals” or “the Company”) (NYSE: CMP) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CMP .
  • If you suffered a loss in Compass Minerals you have until June 24, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Retrieved on: 
星期三, 五月 8, 2024
Compass, Administration, Safety, Post-traumatic stress disorder, Nausea, Neuroscience, Trauma, The Institute, Psychology, Crying, Disability, Suicidal ideation, History, SDS, Mental health, Patient, Fatigue, Headache, Sunstone, Suicide, Diagnosis, Quality of life, CMPS, Pharmaceutical industry

“These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.

Key Points: 
  • “These results, with early and lasting improvement in symptoms following a single administration of COMP360, are highly encouraging,” said Dr.
  • “These observations, even with a small, open-label study, suggest that COMP360 could provide a clinically meaningful benefit and substantially improve patient daily function and quality of life.
  • The well tolerated safety profile for COMP360 in patients with PTSD, with no serious adverse events observed, advance our understanding of potential applications of COMP360.
  • Compass previously announced 24-hour safety data from the study, which indicated that COMP360 was well-tolerated, with no treatment emergent serious adverse events.

DEADLINE ALERT for CMP and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
星期五, 五月 3, 2024
Compass, Compass Minerals, Malibu Boats, Investment, Suite, Law, Defendant, Boat, Security (finance)

LOS ANGELES, May 03, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, May 03, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Automated Material Handling Equipment Market worth $51.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期四, 五月 2, 2024
Risk, Form factor, AC, Automation, Digital technology, PCB, Unit load, Food, Tag, Robotics, WMS, Compass, KION, Transport, Safety, Statistics, Carousel, Automotive industry, Ultra, AGV, Pallet, SSI, Government, SCARA, AC/DC, AMR, Software, Forklift, Panel, System, Fourth Industrial Revolution, COVID-19, Growth, Warehouse

These elements place the automobile industry in a prominent position to propel the market for automated material handling systems.

Key Points: 
  • These elements place the automobile industry in a prominent position to propel the market for automated material handling systems.
  • WMS Product grows at the highest CAGR in the Automated Material Handling Market during the forecast period.
  • Warehouse Management Systems (WMS) are anticipated to exhibit the highest CAGR within the automated material handling equipment industry for several key reasons.
  • The market for automated material handling equipment is expected to grow at the fastest rate in the Asia Pacific region.

Automated Material Handling Equipment Market worth $51.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期四, 五月 2, 2024
Risk, Form factor, AC, Automation, Digital technology, PCB, Unit load, Food, Tag, Robotics, WMS, Compass, KION, Transport, Safety, Statistics, Carousel, Automotive industry, Ultra, AGV, Pallet, SSI, Government, SCARA, AC/DC, AMR, Software, Forklift, Panel, System, Fourth Industrial Revolution, COVID-19, Growth, Warehouse

These elements place the automobile industry in a prominent position to propel the market for automated material handling systems.

Key Points: 
  • These elements place the automobile industry in a prominent position to propel the market for automated material handling systems.
  • WMS Product grows at the highest CAGR in the Automated Material Handling Market during the forecast period.
  • Warehouse Management Systems (WMS) are anticipated to exhibit the highest CAGR within the automated material handling equipment industry for several key reasons.
  • The market for automated material handling equipment is expected to grow at the fastest rate in the Asia Pacific region.

Warehouse Management System Market worth $8.6 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期一, 四月 29, 2024
Cloud, Aerial, Amazon, Environment, Condition monitoring, PAM, Machine vision, E-commerce, Unit load, Food, Software, Robotics, Digital twin, WMS, Logistics, HMI, Compass, PTC, EBay, Ecosystem, Transport, SME, Statistics, Personal, Automotive industry, AGV, Automation, Microsoft, Pallet, SSI, Inspection, ASRS, SAP, SCARA, AMR, Component, Ali Baba, Forklift, Crane, MES, System, Schaefer Group, Growth, IBM, Video game

The advancement in industrial automation has led to the integration of new technologies and features into Warehouse Management Systems (WMS).

Key Points: 
  • The advancement in industrial automation has led to the integration of new technologies and features into Warehouse Management Systems (WMS).
  • The cloud-based warehouse management systems market is expected to grow at a higher CAGR during the forecast period.
  • North America held the largest share of the warehouse management system market in 2023.
  • The US plays a crucial role in driving the growth of the warehouse management system industry within North America.

Warehouse Management System Market worth $8.6 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
星期一, 四月 29, 2024
Cloud, Aerial, Amazon, Environment, Condition monitoring, PAM, Machine vision, E-commerce, Unit load, Food, Software, Robotics, Digital twin, WMS, Logistics, HMI, Compass, PTC, EBay, Ecosystem, Transport, SME, Statistics, Personal, Automotive industry, AGV, Automation, Microsoft, Pallet, SSI, Inspection, ASRS, SAP, SCARA, AMR, Component, Ali Baba, Forklift, Crane, MES, System, Schaefer Group, Growth, IBM, Video game

The advancement in industrial automation has led to the integration of new technologies and features into Warehouse Management Systems (WMS).

Key Points: 
  • The advancement in industrial automation has led to the integration of new technologies and features into Warehouse Management Systems (WMS).
  • The cloud-based warehouse management systems market is expected to grow at a higher CAGR during the forecast period.
  • North America held the largest share of the warehouse management system market in 2023.
  • The US plays a crucial role in driving the growth of the warehouse management system industry within North America.

COMPASS MINERALS INTERNATIONAL, INC. (NYSE: CMP) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Compass Minerals International, Inc.

Retrieved on: 
星期四, 四月 25, 2024
Compass, Compass Minerals, News, Complaint, ARE, COMPASS, Action Replay, District court, Court, Advertising, Security (finance)

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Compass Minerals International, Inc. (NYSE: CMP)?
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Compass Minerals International, Inc. (“Compass Minerals” or the “Company”) (NYSE: CMP) between November 29, 2023 and March 22, 2024, inclusive (the “Class Period”).
  • If you purchased or acquired Compass Minerals securities, and/or would like to discuss your legal rights and options please visit Compass Minerals International, Inc.
  • If you purchased or acquired Compass Minerals securities, and/or would like to discuss your legal rights and options please visit Compass Minerals International, Inc.

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Retrieved on: 
星期四, 四月 25, 2024
Compass, FDA, FTD, Paclitaxel, Food, BTC, Survival, R&D, MD, Doctor of Philosophy, Fast track (FDA), Observation, Therapy, Patient, Pharmaceutical industry

CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study

Key Points: 
  • CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study
    Top-line data readout for COMPANION-002, the Company’s randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024
    BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced BTC that have been previously treated.
  • “We are delighted that CTX-009 has received FDA Fast Track Designation highlighting the large unmet need in patients with advanced BTC where current therapies have low, single digit response rates, and limited effect on patient survival,” said Thomas Schuetz, MD, PhD, Co-founder, President of R&D, and Vice Chairman of the Compass board.
  • “Our current study is evaluating the combination of CTX-009 with paclitaxel following the observation of nine partial responses in 24 patients treated in our Phase 2 study, leading to an overall response rate of 37.5% (n= 9/24), a median progression free survival of 9.4 months and a median overall survival of 12.5 months.
  • Compass remains on track to complete enrollment by mid-year and reporting top-line data by year end.”